Market Overview

UPDATE: JP Morgan Upgrades Allscripts Healthcare Solutions to Overweight: Valuation Depressed

Related MDRX
Allscripts Has 20% Upside: Deutsche Bank Upgrades Stock To Buy
The Market In 5 Minutes

JP Morgan raised its rating on Allscripts Healthcare Solutions (NASDAQ: MDRX) from Neutral to Overweight and increased its price target from $12 to $15.

JP Morgan noted, "2Q results from MDRX showed that the business overall is on a much more stable footing than we would have expected in light of the board turmoil and earnings miss last quarter. …MDRX shares trade at less than 10x 2013E EPS, close to trough levels. Even at $10.30 as indicated in the after-market, we believe the shares present an attractive value, and we expect the multiple to revert to ~15x over the next twelve months, more in line with what we would view as stable earnings growth of 10-15% over the next few years for the company."

Allscripts Healthcare Solutions closed at $9.60 on Wednesday.

Latest Ratings for MDRX

Mar 2017Wells FargoUpgradesMarket PerformOutperform
Feb 2017DoughertyUpgradesNeutralBuy
Jan 2017Cantor FitzgeraldInitiates Coverage OnNeutral

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (MDRX)

View Comments and Join the Discussion!